The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of neoadjuvant hormone therapy on the permanent 125I-seed brachytherapy for low- or intermediate-risk prostate cancer.
Ryuta Tanimoto
No relevant relationships to disclose
Kensuke Bekku
No relevant relationships to disclose
Shin Ebara
No relevant relationships to disclose
Motoo Araki
No relevant relationships to disclose
Hiroyuki Yanai
No relevant relationships to disclose
Norihisa Katayama
No relevant relationships to disclose
Yasutomo Nasu
No relevant relationships to disclose
Hiromi Kumon
No relevant relationships to disclose